BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023
MAINZ, Germany, March 13, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial...
Pharmaceutical
Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering...
Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update
Plan to commence Phase 1b/2 clinical trial in US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM)...
Ventyx Biosciences Provides Update on Silicon Valley Bank Financial Exposure
ENCINITAS, Calif., March 11, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), has learned that Silicon Valley Bank...
Cytovance Biologics and Phenotypeca Collaborate to Enhance Saccharomyces cerevisiae Strain Development for Microbial Biomanufacturing
OKLAHOMA CITY, March 11, 2023 (GLOBE NEWSWIRE) -- Cytovance Biologics, Inc. (Cytovance Biologics), a biopharmaceutical contract development and manufacturing organization...
Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank
LOS ANGELES, March 10, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical...
Mersana Therapeutics Provides Statement About SVB
CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering...
Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference
FORT LEE, NJ, March 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the...
PetVivo Holdings, Inc. to Exhibit and Dr. Erik Kleeman of Ethos Veterinary Health to Present Canine Study Results at the Veterinary Orthopedic Society Annual Conference
MINNEAPOLIS, MN, US, March 10, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo")...
89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 – – Feedback from FDA...
Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
MALVERN, Pa., March 10, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing...
Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments
Recent acquisition of Phase 3-ready SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the...
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
SAN MATEO, Calif. and SINGAPORE, March 10, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical...
Enterome’s Management to Attend Upcoming Meetings
Paris, France – March 10, 2023 Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based...
First Wave BioPharma Announces Second Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation in Cystic Fibrosis
Three U.S. clinical trial sites actively screening and enrolling patients; Topline data expected by mid-2023BOCA RATON, Fla., March 10, 2023...
Aseptic Filling of Small Volumes at High Precision
Filling accuracy has become increasingly important for laboratories and biopharmaceutical manufacturers. Single Use Support has developed best-in-class filling precision for...
Predictive Oncology Issues Letter to Shareholders
Signature of Raymond F. Vennare, Chief Executive Officer Signature of Raymond F. Vennare, Chief Executive OfficerEAGAN, Minn., March 09, 2023...
Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference
Qualigen Therapeutics, Inc. F3 Compounds Cooperate with Checkpoint Inhibitors and Other RAS Inhibitors Qualigen Therapeutics, Inc. F3-8-60 inhibits RAS RAF...
Blue Water Vaccines Reports Year 2022 Financial Results and Recent Business Highlights
CINCINNATI, March 09, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today...
LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors
UTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company...